Altered microbiota and inflammation associated with irritable bowel disease (IBD) appear to make it more difficult for patients to fight off Clostridioides difficile infection, according to a recent ...
Risk for Clostridioides difficile (C. diff) infection wasn't any greater with vedolizumab (Entyvio) versus anti-tumor necrosis factor (TNF) agents for ulcerative colitis, a researcher reported. In a ...
Clostridioides difficile infection among patients hospitalized with IBD is linked to higher mortality, more complications, and more health care use.
Research at North Carolina State University shows that the CRISPR-Cas system can be used to effectively target and eliminate specific gut bacteria, in this case Clostridioides difficile, the pathogen ...
VE202 was well tolerated, with no reports of treatment-related serious adverse events Additional analyses from COLLECTiVE202 to be shared in upcoming scientific forums Vedanta to focus resources on ...
Vedolizumab (Entyvio) treatment was linked with a lower risk of some infections compared with tumor necrosis factor (TNF) antagonists in patients with ulcerative colitis (UC), researchers reported. An ...
Research at North Carolina State University shows that the CRISPR-Cas system can be used to effectively target and eliminate specific gut bacteria, in this case Clostridioides difficile, the pathogen ...
Fecal microbiota transplants are the most effective and affordable treatment for recurrent infections with Clostridioides difficile, an opportunistic bacterium and the most common cause of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results